- Home
- OABI vs DFP Comparison
OABI vs DFP Comparison
Compare OABI & DFP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- DFP
- Stock Information
- Founded
- OABI 2012
- DFP 2013
- Country
- OABI United States
- DFP United States
- Employees
- OABI N/A
- DFP N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- DFP Investment Managers
- Sector
- OABI Health Care
- DFP Finance
- Exchange
- OABI Nasdaq
- DFP Nasdaq
- Market Cap
- OABI 459.1M
- DFP 418.2M
- IPO Year
- OABI N/A
- DFP N/A
- Fundamental
- Price
- OABI $3.85
- DFP $20.16
- Analyst Decision
- OABI Strong Buy
- DFP
- Analyst Count
- OABI 4
- DFP 0
- Target Price
- OABI $9.00
- DFP N/A
- AVG Volume (30 Days)
- OABI 509.5K
- DFP 56.2K
- Earning Date
- OABI 11-12-2024
- DFP 01-01-0001
- Dividend Yield
- OABI N/A
- DFP 6.73%
- EPS Growth
- OABI N/A
- DFP N/A
- EPS
- OABI N/A
- DFP N/A
- Revenue
- OABI $20,409,000.00
- DFP N/A
- Revenue This Year
- OABI N/A
- DFP N/A
- Revenue Next Year
- OABI $71.78
- DFP N/A
- P/E Ratio
- OABI N/A
- DFP N/A
- Revenue Growth
- OABI N/A
- DFP N/A
- 52 Week Low
- OABI $3.56
- DFP $15.45
- 52 Week High
- OABI $6.72
- DFP $19.31
- Technical
- Relative Strength Index (RSI)
- OABI 40.94
- DFP 36.14
- Support Level
- OABI $3.62
- DFP $20.17
- Resistance Level
- OABI $4.19
- DFP $20.45
- Average True Range (ATR)
- OABI 0.23
- DFP 0.20
- MACD
- OABI -0.06
- DFP -0.02
- Stochastic Oscillator
- OABI 18.40
- DFP 7.23
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Pref&Inc Allocation is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.